How Effective Is Wegovy 7.2mg? Clinical Trial Results Explained

Many people considering weight-management treatment want to know whether higher doses of medication can lead to better results.

Wegovy contains semaglutide, a medication that works by mimicking the hormone GLP-1 to help regulate appetite, increase feelings of fullness and reduce hunger. It is designed to support weight loss when used alongside a balanced diet and regular physical activity.

The 7.2 mg dose of Wegovy has been studied in clinical trials to assess whether it may help some patients achieve additional weight loss compared with the previous maximum dose of 2.4 mg.

If a higher dose is considered appropriate, patients in the UK may be able to access Wegovy treatment through regulated online pharmacy services such as Pharmacy Planet, following a medical consultation with a qualified prescriber.

What do clinical trials say about Wegovy 7.2mg?

Clinical research has explored whether higher doses of semaglutide could support greater weight loss outcomes.

One of the key studies investigating this was the STEP-UP clinical trial, which evaluated the effectiveness of a 7.2 mg weekly dose of semaglutide in adults living with overweight or obesity.

In this study, participants who received 7.2 mg once weekly lost an average of around 21% of their starting body weight over 72 weeks, when the treatment was combined with lifestyle changes such as a reduced-calorie diet and increased physical activity.

For comparison:

• Participants taking 2.4 mg lost around 17% of their starting body weight
• Participants taking a placebo lost around 2–3%

These results suggest that increasing the dose to 7.2 mg may provide additional weight-loss support for some patients, particularly those who may have reached a plateau on lower maintenance doses.

However, clinical trials measure averages across many participants, meaning individual results can vary.

Wegovy 7.2mg vs 2.4mg: clinical trial comparison

Results from the STEP-UP trial showed differences in weight-loss outcomes between the 7.2 mg dose, the 2.4 mg dose and placebo over a 72-week period.

The higher dose was also associated with more patients reaching significant weight-loss milestones compared with the lower maintenance dose.

Does Wegovy 7.2mg help more people reach weight-loss milestones?

Researchers also looked at how many participants reached specific weight-loss milestones during treatment.

The findings showed that a greater proportion of patients taking the 7.2 mg dose achieved higher levels of weight loss compared with those taking the 2.4 mg dose.

These milestones included losing at least:

• 5% of their starting body weight
• 10% of their starting body weight
• 15% or more of their starting body weight
• 20% or more of their starting body weight

Reaching these milestones can be meaningful, as even moderate weight loss may help support improvements in overall health.

However, results can vary between individuals.

Prescribers at services such as Pharmacy Planet may review your treatment progress regularly to ensure the medication and dose remain appropriate for your individual weight-management goals.

Can everyone achieve the same results with Wegovy 7.2mg?

Although clinical trials suggest that the higher dose may offer additional benefits for some patients, weight-loss outcomes are not the same for everyone.

Several factors can influence how effective treatment may be, including:

• metabolism
• lifestyle habits
• physical activity levels
• adherence to treatment
• underlying health conditions, especially those related to the heart.

Because of this, healthcare professionals usually review progress throughout treatment.

If appropriate, patients in the UK can buy Wegovy treatment through licensed online pharmacies such as Pharmacy Planet, where prescribers assess whether the medication and dose are suitable before it can be supplied.